A significant bipartisan push is underway in Washington to expand medical cannabis access for US military veterans, with new legislation and funding provisions set to reshape the Department of Veterans Affairs (VA) approach to the treatment. The Veterans Cannabis Analysis and Research Act (VCARA), reintroduced in the Senate on 14 March 2026 by Senators Brian Schatz (D-HI) and Dan Sullivan (R-AK), seeks to finally allow VA doctors to recommend medical cannabis in states where it is legal, ending a long-standing federal prohibition that advocates argue has left many veterans without effective pain management options.
Breaking the Federal Barrier: The VA Cannabis Research Act
Central to the reform is the VA Cannabis Research Act, a companion bill to VCARA that cleared the Senate Veterans’ Affairs Committee on 22 April 2026 by an 18-2 vote. The Act mandates the VA to conduct large-scale clinical trials on the efficacy of cannabis for chronic pain, post-traumatic stress disorder (PTSD), and traumatic brain injury—conditions disproportionately affecting the veteran community. Under current law, VA doctors are barred from completing medical cannabis recommendation forms, even in the 38 states with legal medical programmes. ‘This is about giving veterans the same treatment options as civilians,’ said Senator Schatz during the committee markup. ‘We have mountains of anecdotal evidence; it is time for rigorous, federally funded research to guide policy.’
Veterans’ Organisations Testify: ‘This Is a Health Crisis, Not a Crime’
Testimony before the committee on 10 March 2026 highlighted the human cost of the status quo. ‘We have veterans self-medicating with black-market cannabis, risking contamination and arrest, because the VA offers opioids as the only alternative,’ testified Sara Nelson, policy director for Veterans for Medical Cannabis Access. The American Legion and Disabled American Veterans both submitted letters of support, noting that nearly one in three veterans in states with legal cannabis use it for symptom relief. ‘The federal government has a moral obligation to remove barriers to safe, regulated care,’ added retired Army Colonel James Whitaker, who testified about his own PTSD regimen under California’s medical cannabis programme. Opponents, including some conservative lawmakers, cited a lack of Food and Drug Administration (FDA) approval and concerns about long-term cognitive effects, though the committee’s bipartisan vote suggests shifting political winds.
Fiscal Year 2027 Funding Provisions: A $25 Million Commitment
The push for access is bolstered by a $25 million allocation embedded in the proposed Fiscal Year 2027 VA budget, released by the White House on 7 February 2026. The funding, earmarked for a new ‘Cannabis Research and Clinical Implementation Office’ within the VA, would support the clinical trials mandated by the Cannabis Research Act and underwrite training for VA doctors on state medical cannabis programmes. ‘This is not about promoting recreational use; it is about giving doctors the tools to recommend a treatment that works for some of our most vulnerable patients,’ explained VA Secretary Denise McDonough during a 19 May 2026 press conference. The provision also includes a directive to harmonise VA policies with state medical cannabis laws by 1 October 2026, the start of the fiscal year. While the budget faces debate in the House Appropriations Committee, where some Republicans have signalled resistance, the combination of bipartisan legislation and dedicated funding marks the most serious attempt yet to end the federal prohibition on VA cannabis recommendations. For the 9 million veterans enrolled in the VA system, the clock is now ticking towards a potential watershed moment in medical cannabis policy.
